PMID: 6969778Jan 1, 1981Paper

In vitro analysis of allogeneic lymphocyte interaction. V. Identification and characterization of two components of allogeneic effect factor, one of which displays H-2-restricted helper activity and the other, T cell-growth factor activity

The Journal of Experimental Medicine
T L DelovitchV Paetkau

Abstract

An allogeneic effect factor (AEF) derived from mixed lymphocyte reaction (MLR) cultures of alloactivated A.SW (H-2s) responder T cells and irradiated A/WySn (H-2a) stimulator spleen cells helps an in vitro primary anti-erythrocyte plaque-forming cell PFC response of BALB/c nude spleen cels and also A/WySn but not A.SW T cell-depleted spleen cells. AEF activity is adsorbed by anti-Ik and anti-I-Ak but not by anti-I-Jk, anti-I-ECk, and anti-Is. Gel filtration of ACA 54 resolves AEF into two main components that which appear in the 50,000- to 70,000-mol wt (component I) and 30,000- to 35,000-mol wt (component II) regions, respectively. Component I has a mol wt of 68,000, elutes from DEAE-Sephacel at 0.05-0.1 M NaCl, and has an isoelectric point (pI) of 5.8. It helps A/WySn but not A.SW B cells and, therefore, is H-2 restricted. Component II is not H-2 restricted, because it helps both A.SW and A/WySn B cells. It also stimulates (a) the growth of a long-term cytotoxic cell line in vitro, (b) Con A-induced thymocyte mitogenesis, and (c) the generation of cytotoxic T cells. The latter three properties of component II are not shared by component I. In addition, component II elutes from DEAE-Sephacel at 0.15-0.2 M NaCl and has a pI of ...Continue Reading

References

Nov 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·C G Fathman, H Hengartner
Oct 1, 1978·The Journal of Experimental Medicine·P P JonesH O McDevitt
Jan 1, 1977·Immunological Reviews·H Cantor, E A Boyse
Mar 25, 1977·Science·W E Paul, B Benacerraf
Jan 1, 1977·Journal of Immunological Methods·J J LangoneT Borsos
Aug 15, 1975·European Journal of Biochemistry·R A Laskey, A D Mills
Aug 1, 1974·Analytical Biochemistry·T PooleW W Fish
Feb 14, 1980·Nature·E L LarssonA Coutinho
Jan 1, 1980·Immunological Reviews·V PaetkauB Caplan

❮ Previous
Next ❯

Citations

Jan 1, 1982·Immunogenetics·M SuzanB Rubin
Apr 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·J Anderson, F Melchers
Jan 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·L J Yaffe, F D Finkelman
Mar 1, 1982·The Journal of Experimental Medicine·P C IsaksonP H Krammer
Mar 1, 1984·The Journal of Experimental Medicine·A L DeFrancoW E Paul
Jan 1, 1982·Annals of the New York Academy of Sciences·A TominagaM I Greene
Jan 1, 1982·Immunological Reviews·A L DeFrancoW E Paul
Jan 1, 1982·Journal of Cellular Physiology. Supplement·F Melchers
Jan 1, 1982·Journal of Cellular Biochemistry·F MelchersJ Zeuthen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.